Review
Biochemistry & Molecular Biology
Ajay Dhakal, Luna Acharya, Ruth O'Regan, Shipra Gandhi, Carla Falkson
Summary: The derangement of the PI3K pathway is closely related to various subtypes of breast cancer, making it a promising molecular target for systemic therapy. While several drugs targeting PI3K have been or are being investigated in clinical trials, the search for an effective and safe PI3K inhibitor for breast cancer treatment continues. This review focuses on completed and ongoing clinical trials of PI3K inhibitors in breast cancer, highlighting their efficacy and potential challenges.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Quchang Ouyang, Ying Wang, Jian Zhang, Qiong Wu, Hongying Wei, Chuan Li, Xiaoling Qian, Xichun Hu
Summary: This study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of HS-10352, a selective PI3K alpha inhibitor, in patients with HR-positive, HER2-negative ABC. The results showed that HS-10352 at a dosage of 6 mg once-daily was well-tolerated and showed preliminary antitumor activity in patients with PIK3CA mutated tumors.
Article
Oncology
Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang, Binghe Xu
Summary: Less than one quarter of patients initiated palliative ET for HR+ ABC in routine clinical practice. Patients who received multi-lines of ET experienced successive shorter durations following each line of therapy. This real-life data provides a solid overview of ET for HR+ ABC from China, indicating unmet need for treatment options that improve the effectiveness of endocrine therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Eunice Yoojin Lee, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im
Summary: Hormone receptor-positive (HR+) breast cancer is the most common subtype with a favorable prognosis. Endocrine therapy, targeting steroid hormone signaling, is the main treatment option. The discovery of cyclin-dependent kinase 4/6 inhibitors has greatly improved the treatment outcome of advanced HR+ breast cancer. Additionally, targeted therapy, inhibitors, antibody-drug conjugates, and immunotherapeutic agents have expanded the available therapeutic options.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Medicine, General & Internal
Jason A. Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debasish Tripathy, Rachel M. Layman
Summary: This study aimed to investigate the association between low ERBB2 expression and prognosis in HR-positive metastatic breast cancer (mBC) patients treated with targeted therapy (TT) plus endocrine therapy (ET). The results showed that low ERBB2 expression was not significantly associated with prognosis in this population.
Review
Immunology
Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Summary: ICB has revolutionized cancer treatment, but has limited efficacy in HR+ breast cancer due to a TME devoid of TILs. TNBC shows clinical responses to ICB due to TIL infiltration, while HR+ breast tumors establish an immune suppressive TME.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
William Sebastian, Lauren Forchette, Kelsey Donoughe, Yibei Lun, Anisha Verma, Tuoen Liu
Summary: In this review paper, various important aspects of hormone receptor (HR)-positive breast cancer were discussed, including HR structure and signaling, genetics (epigenetics and gene mutations), gene expression-based assays, traditional and new drugs for treatment, and new technological uses in diagnosis and treatment. Particularly, the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer were summarized, and the common gene expression-based assays used in breast cancer as prognostic and/or predictive tools were compared in detail. These topic discussions have not been fully described and summarized within other research or review articles.
Review
Oncology
Y. Wang, H. Xu, Y. Han, Y. Wu, Q. Sa, J. Wang
Summary: This systematic review and network meta-analysis aimed to solve the treatment controversy of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The results showed that endocrine therapy had better efficacy in prolonging progression-free survival and overall survival compared with chemotherapy, and had similar safety profiles.
Review
Pharmacology & Pharmacy
Elizabeth Hageman, Mia E. Lussier
Summary: This article discusses the approval and efficacy of elacestrant in the treatment of hormone receptor positive (HR+) advanced breast cancer. It shows that elacestrant is a potentially effective alternative for patients with ESR1 mutations who have failed previous therapies. Elacestrant has a comparable safety profile to other endocrine therapies and can be used after traditional chemotherapy.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Oncology
Yimin Zhu, Jiayu Wang, Binghe Xu
Summary: The study successfully established a nomogram model to predict overall survival in HR+/HER2- subtype advanced breast cancer patients, which accurately predicted the survival outcomes and assisted physicians in making personalized therapeutic options.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Angelica Ferrando-Diez, Eudald Felip, Anna Pous, Milana Bergamino Sirven, Mireia Margeli
Summary: In recent years, the development of anti-HER2 treatments has improved the landscape of HER2-positive breast cancer. However, relapse remains a major issue. This review focuses on the milestones that have impacted the disease and highlights the importance of understanding the underlying molecular biology for optimizing treatment options. The review also discusses the role of triple-positive disease and modulation of the immune response in treatment and prognosis.
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Medicine, General & Internal
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Summary: Capivasertib-fulvestrant therapy significantly improves progression-free survival in patients with hormone receptor-positive advanced breast cancer, particularly those with AKT pathway alterations.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Editorial Material
Medicine, General & Internal
Sharon H. Giordano
Summary: Advances in cancer screening and treatment have increased the number of cancer survivors. These survivors may face long-term and late effects, including infertility due to cancer treatments. Addressing the possibility of infertility is recommended, especially for young cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
S. J. Luen, G. Viale, S. Nik-Zainal, P. Savas, R. Kammler, P. Dell'Orto, O. Biasi, A. Degasperi, L. C. Brown, I. Lang, G. MacGrogan, C. Tondini, M. Bellet, F. Villa, A. Bernardo, E. Ciruelos, P. Karlsson, P. Neven, M. Climent, B. Mueller, W. Jochum, H. Bonnefoi, S. Martino, N. E. Davidson, C. Geyer, S. K. Chia, J. N. Ingle, R. Coleman, C. Solbach, B. Thurlimann, M. Colleoni, A. S. Coates, A. Goldhirsch, G. F. Fleming, P. A. Francis, T. P. Speed, M. M. Regan, S. Loi
Summary: This study analyzed the genomic alterations in young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer. The results identified genomic features associated with poor prognosis and provided insight into potential molecular targets for future clinical trials.
ANNALS OF ONCOLOGY
(2023)
